ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

CRON vs DFTX // OPTIONS IMPLIED MOVE & PUT/CALL SKEW

Cronos Group Inc. Common Share (NASDAQ) VS. Definium Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: CRON 5 — DFTX 4
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CRON VS. DFTX) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC CRON DFTX SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 42.80% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -4.50% -32.20% +27.70 CRON /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield 0.01% -3.84% +3.85 CRON /fcf-yield <GO>
Operating Margin -11.90% -11.60% -0.30 DFTX /operating-margins <GO>
Net Profit Margin -2.00% -12.90% +10.90 CRON /net-margins <GO>
Revenue Growth (YoY) 24.60% 5.50% +19.10 CRON /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 15.20 26.00 -10.80 DFTX /balance-sheet <GO>
Piotroski F-Score Quality 6/9 5/9 +1.00 CRON /piotroski-score <GO>
Options Implied Move & Put/Call Skew ACTIVE — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 55.0 55.4 -0.40 DFTX /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — 1.08 — TIE /macro-sensitivity <GO>
Forward P/E Multiple — 33.0x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $1.24B $5.10B -$3.86B DFTX /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR CRON REV DFTX REV CRON GROSS % DFTX GROSS % CRON FCF DFTX FCF
FY 2025 $146.6M $0 42.8% — $149.0K -$131.6M
FY 2024 $117.6M $0 21.4% — $6.4M -$79.1M
FY 2023 $87.2M $0 — — -$42.8M -$64.4M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CRON // BETA —
DFTX // BETA 1.08